Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Condition(s) studied
Investigational drug(s) / intervention(s)
blood sample HBV patient: During a boold sample at only one follow up visit: * 3 tubes EDTA 10 ml per patient * 1 tube "Paxgene" 1ml * 2 dry tube per patient
blood sample healthy volunteers: * 3 tubes EDTA ideally age and sex matched to CHB patient. * 1 tube "Paxgene" 1ml * 2 dry tube
Study summary
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.
Eligibility
Primary outcome measure(s)
- RNA sequencing of B cells from CHB patients at different stages, description of their molecular signature — At inclusion, day 0
Trial sites (3)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre d'Investigation Clinique | Limoges | France | Recruiting |
| Limoges University Hospital | Limoges | France | Recruiting |
| Hospice civils de Lyon | Lyon | France | Recruiting |
More University Hospital, Limoges trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06853886 on ClinicalTrials.gov ↗ ← All trials in France